ANNOVIS BIO
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
ANNOVIS BIO
Industry:
Biotechnology Developer Platform Therapeutics
Founded:
2008-01-01
Address:
Berwyn, Pennsylvania, United States
Country:
United States
Website Url:
http://www.annovisbio.com
Total Employee:
1+
Status:
Active
Contact:
(610)727-3913
Email Addresses:
[email protected]
Total Funding:
58.98 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro GStatic Google Static Content Sectigo SSL Sectigo Domain SSL PostalAddress Schema
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Employees Featured
Founder
Stock Details
Investors List
Robin Hood Ventures
Robin Hood Ventures investment in Post-IPO Equity - Annovis Bio
Robin Hood Ventures
Robin Hood Ventures investment in Series A - Annovis Bio
Robin Hood Ventures
Robin Hood Ventures investment in Series A - Annovis Bio
Delaware Crossing Investor Group
Delaware Crossing Investor Group investment in Series A - Annovis Bio
Michael Hoffman
Michael Hoffman investment in Series A - Annovis Bio
Keiretsu Forum
Keiretsu Forum investment in Series A - Annovis Bio
BioAdvance
BioAdvance investment in Seed Round - Annovis Bio
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania investment in Seed Round - Annovis Bio
BioAdvance
BioAdvance investment in Debt Financing - Annovis Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-29 | Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer |
Official Site Inspections
http://www.annovisbio.com Semrush global rank: 4.5 M Semrush visits lastest month: 2.39 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
